
CVRx (CVRX) Stock Forecast & Price Target
CVRx (CVRX) Analyst Ratings
Bulls say
CVRx is off to a strong start in 2026, with preliminary Q1 revenue and gross margin both exceeding expectations and guidance. The company has a solid balance sheet with significant cash and is well-positioned for continued rep productivity gains and growth through the BENEFIT-HF trial, which could expand its TAM by 3x. However, there is still a level of risk associated with the company's heavy dependence on a single product for revenue, limited long-term clinical data, and the potential for future losses and dilution.
Bears say
CVRx is a commercial-stage medical device company with a proprietary platform technology focused on treating cardiovascular diseases. While they have a strong revenue model and have announced positive updates, such as CMS Category B coverage for the BENEFIT-HF trial and the implementation of Category I CPT codes, the company is facing challenges with lower active account numbers and a decline in the small-cap med-tech comp group multiple. This, along with the potential for continued salesforce disruption, leads to a negative outlook on CVRx's stock as their growth may be limited in the near future.
This aggregate rating is based on analysts' research of CVRx and is not a guaranteed prediction by Public.com or investment advice.
CVRx (CVRX) Analyst Forecast & Price Prediction
Start investing in CVRx (CVRX)
Order type
Buy in
Order amount
Est. shares
0 shares